Company Filing History:
2 out of 1,930 
2 out of 2,925 
Years Active: 2021
Title: **Innovative Contributions of Wishrawana Sarathi Ratnayake in Melanoma Treatment**
Introduction
Wishrawana Sarathi Ratnayake, based in Tampa, FL, is a prominent inventor known for his work in the field of melanoma treatment. With two patents to his name, he has made significant strides in developing innovative methods for addressing this challenging disease. His research focuses on the use of atypical protein kinase C inhibitors to provide alternative therapeutic solutions for melanoma patients.
Latest Patents
Ratnayake's notable contributions include a method of treating melanoma using inhibitors of atypical protein kinase C. This invention involves administering a composition containing a therapeutically effective amount of an inhibitor of PKC-θ and/or PKC-η to individuals in need. Notably, ICA-1 and ACPD are highlighted as examples of such inhibitors. The patent also underscores the potential of PKC-θ and/or PKC-η as biomarkers, helping to identify whether a subject with melanoma is likely to respond positively or negatively to specific therapies. Additionally, the method allows for assessing the levels and activity of these proteins in melanoma cells,which can guide treatment decisions.
Career Highlights
Ratnayake has collaborated with esteemed organizations, including the University of South Florida and the University of Florida Research Foundation. His experience in these institutions reflects his commitment to advancing the field of cancer research and his dedication to finding effective therapeutic measures against melanoma.
Collaborations
Throughout his career, Ratnayake has worked alongside accomplished experts, including Mildred Enid Acevedo-Duncan and David A Ostrov. Their combined expertise contributes to a stronger understanding of melanoma biology and the development of innovative treatment strategies.
Conclusion
Wishrawana Sarathi Ratnayake's contributions to melanoma research have heralded promising developments in treatment methodologies. With his patent work paving the way for potential breakthroughs, he remains an influential figure in the field of medical innovation, dedicated to improving patient outcomes in melanoma therapy.